gdc

Web Exclusives

Why Every Patient with Cancer Needs a Strong Support System
Support Services
Every person with cancer can benefit from a support system that can help manage the physical and emotional aspects of cancer care, as well as help with daily struggles.
A Look at First-Line CLL Treatment in 2021
CLL Monthly MinutesLeukemia
Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future.
Analysis Shows Unmet Needs in Quality-of-Life Studies in Patients with CLL
CLL Monthly MinutesLeukemia
A literature review found a set of physical, psychological, social, and spiritual topics that could be used to better educate patients throughout their CLL treatment journey.
Reduced Efficacy of COVID-19 Vaccination in Immunocompromised Patients
CLL Monthly MinutesLeukemia
COVID-19 vaccination is generally safe for immunocompromised patients, including those with CLL, although the efficacy is substantially lower than in healthy individuals.
Early Results for a Promising New BCL-2 Inhibitor
CLL Monthly MinutesLeukemia
Cell-based assays and animal data suggest that ZN-d5 may be a tolerable and effective treatment for patients with leukemias and lymphomas.
Why It Helps to Share Your Cancer Story and How to Get Started
Sharing your cancer story can promote your sense of what’s truly important, giving you hope and strength in difficult times.
Treating Rare Cancers Can Be Hard: Why Genomic Testing Is Crucial
Genomic TestingCholangiocarcinoma
Jim Palma and John Hopper, Co-Chairs of NORD Rare Cancer Coalition, explain the difference between genetic testing and genomic profile testing, and why all patients with rare cancers should have a genomic profile done to select the best treatment for them based on potential genomic alteration.
Acalabrutinib versus Ibrutinib in Previously Treated CLL
CLL Monthly MinutesLeukemia
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib.
Protecting Patients with CLL from COVID-19
CLL Monthly MinutesLeukemia
A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.
Promising Data on Zanubrutinib in Previously Treated CLL
CLL Monthly MinutesLeukemia
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia.
Page 2 of 22
Results 11 - 20 of 214

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest